For sponsors
One CNS trial, still ramping
107 patients identified · 89 interested
Why enrollment stalls
11%
of sites in a typical trial enroll no patients. Another 37% under-enroll.
Tufts CSDD
$500K
in lost sales for every day a drug reaches market late, on top of about $40K a day in trial cost.
Tufts CSDD, 2024
68%
of physicians who did not refer a patient said they lacked information about the protocol.
BBK Worldwide, 2019
26%
of Americans say a doctor ever discussed a clinical trial with them. 86% think one should.
Research!America, 2017
Who it is for
Clinical operations
Heads of clinical operations, feasibility leads, patient recruitment and trial managers. They own the enrollment timeline and the CRO relationship.
Gets feasibility, investigators, physicians who have your patients, and enrollment tracking.
Medical affairs
MSLs and medical directors. They build the scientific relationships that carry a drug from data into practice.
Gets KOLs ranked by peer-network position and scientific influence, and the questions each one is asking.
Commercial and launch
Launch, field sales and commercial operations. They need the right prescribers on day one.
Gets a ranked list by conversion potential and a brief before every visit.
What your team gets
Clinical
From site feasibility to the last patient enrolled.
Ask the map
How many eligible PAH patients are within 50 miles of Phoenix?
Feasibility: 4 metros ranked
✓ 1,120 eligible patients
01
Site feasibility
Eligible-patient estimates by metro, health system and physician, built from the inclusion criteria before you sign a single site.
02
Investigator identification
A ranked shortlist of principal investigators near each site, with their trial history in your indication and the patient volume behind them.
Called Dr. Castellano
Interested · wants inclusion criteria
Followed up with Dr. Okafor
On sending patients to Site 01
Patient 10349 enrolled
Site 01 · sent by Dr. Bhatt
03
Patient recruitment
Each morning, the physicians who already have eligible patients. Our outreach agent reaches them by email and phone in your name and hands interested physicians to your coordinators.
107 patients identified
One CNS trial, still ramping
89 interested and sent to the site
18 declined
04
Enrollment tracking
Who engaged, who sent a patient, who enrolled, by site and by physician. A heads-up before each patient arrives, and an export to your CTMS on request.
Commercial
From the first KOL to every visit briefed.
AV
Dr. Alex M Vera
Urology · Memorial Sloan Kettering
Clinical Research
Enzalutamide + Leuprolide in nonmetastatic prostate cancer
Phase 3 · Active
Tadalafil after radical prostatectomy
Phase 4 · Completed
Avanafil for ED post-prostatectomy
Phase 3 · Completed
Latest publication: Effects of Enzalutamide on Sexual Activity in Biochemically Recurrent Prostate Cancer, European Urology, 2025
05
KOL identification
For medical affairs, physicians ranked by peer-network position and scientific influence, with their trial history, publications and the questions they have been asking.
Today
7 visits · 88 miles
AV
Dr. Alex M Vera
Urology · Memorial Sloan Kettering (18 mi)
Early Adopter
Strategic first visit: recent publication creates conversion opportunity
RL
Dr. Richard Lang
Internal Medicine · AHF Healthcare Centers (10 mi)
Key Opinion Leader
High-volume KOL with exceptional pharma engagement
06
Smart targeting
For field sales, a ranked list by conversion potential each morning, routed into the day, with the reason each physician is on it. No SQL to write.
AV
Dr. Alex M Vera
Urology · Memorial Sloan Kettering
Early Adopter
Basic Details
Prescription Metrics
Industry Relationships
Clinical Research
Medicare panel of ~404 beneficiaries. Therapeutic focus spans Endocrine/Metabolic, Nephrology/Urology and Oncology.
Hypogonadism
Prostate Cancer
Chronic Pain
Diabetes Mellitus
07
Physician dossiers
Prescribing trends, trial history, publications, industry relationships, hospital affiliations and peer networks. One source of truth for every team.
Tuesday, Oct 29
First Visit
Strategic first visit: recent publication creates conversion opportunity
Primary goal
Convert existing injectable testosterone patients to oral JATENZO
Key message
JATENZO’s oral formulation eliminates injection burden for surgical patients
Opening
Clinical Efficacy
Dosing & Storage
Patient Preferences
Closing
08
Engagement engine
A brief before every visit: the primary goal, the key message, and a playbook from opening to close, with objections anticipated.
The relationship carries over
Clinical operations
Site feasibility
Investigator identification
Patient recruitment
Enrollment tracking
Medical affairs
KOL identification
Scientific exchange
Commercial
Launch targeting
Every visit briefed
Built for biopharma
No PHI leaves the practice
Spellbinder works at the physician level.
HIPAA compliant
Outreach copy MLR approved.
Works with your CRO
Interested physicians go to the site coordinators your CRO already manages.
Zero integration
400+ public datasets, updated in real time. Exports to your CTMS or CRM on request.
What is on the map
Any indication. Especially the rare ones.
1.2M physicians, 7.1M providers and 1.9M organizations-, one profile each from 400+ sources. If a patient exists, so does their doctor, and they are on the map.
Psychiatry
41,000 physicians
Cardiology
33,200 physicians
Endocrinology
26,900 physicians
Oncology
21,700 physicians
Neurology
18,400 physicians
Huntington’s
68 HDSA centers
Duchenne
38 certified care centers
Cystic fibrosis
130+ accredited centers
Pulmonary arterial hypertension
107 accredited centers
Spinal muscular atrophy
29 care center sites
Rett syndrome
20 centers of excellence
Myasthenia gravis
13,900 neurologists
Sickle cell disease
19,900 hematologists
IgA nephropathy
11,600 nephrologists
Eosinophilic esophagitis
15,700 gastroenterologists
Hidradenitis suppurativa
12,800 dermatologists
Fabry disease
Under 2,500 medical geneticists
Your patients have physicians. We find them.
Book a demo